In liver cancer, increasing intratumoral ceramide levels with nanoliposomal administration has been used as a strategy in the treatment of HCC [12], while targeting acid CDase (ACDase) potentiated the cytotoxic effect of daunorubicin in hepatoma cells [13]. Here, ASAH1 is linked to hepatocellular carcinoma.